MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE Drug Patent Profile
✉ Email this page to a colleague
When do Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate patents expire, and what generic alternatives are available?
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is a drug marketed by Santarus and is included in one NDA.
The generic ingredient in MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is magnesium hydroxide; omeprazole; sodium bicarbonate. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium hydroxide; omeprazole; sodium bicarbonate profile page.
Summary for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE at DailyMed |
Recent Clinical Trials for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Valeant Pharmaceuticals International, Inc. | Phase 4 |
| Bausch Health Americas, Inc. | Phase 4 |
| Yvonne Romero | Phase 4 |
See all MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE clinical trials
Anatomical Therapeutic Chemical (ATC) Classes for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
US Patents and Regulatory Information for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-002 | Dec 4, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-002 | Dec 4, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-002 | Dec 4, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
See the table below for patents covering MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 4991432 | ⤷ Try a Trial | |
| European Patent Office | 1246622 | NOUVELLES FORMES POSOLOGIQUES DE BENZIMIDAZOLES SUBSTITUES (NOVEL SUBSTITUTED BENZIMIDAZOLE DOSAGE FORMS AND METHOD OF USING SAME) | ⤷ Try a Trial |
| Germany | 60123381 | ⤷ Try a Trial | |
| Brazil | 0210971 | ⤷ Try a Trial | |
| Israel | 150696 | PHARMACEUTICAL COMPOSITIONS CONTAINING BENZIMIDAZOLE DERIVATIVES AND PROCESSES FOR THE MANUFACTURE THEREOF | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1020461 | 300482 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105 |
| 0984957 | 1290006-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812 |
| 1411900 | 2011C/016 | Belgium | ⤷ Try a Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
| 0124495 | SPC/GB01/006 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1499331 | 13C0055 | France | ⤷ Try a Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
